Alternatives to Alector

A biotechnology company developing genetic therapies for rare disorders.

Biopharmaceutical company targeting neurodegeneration and aging by modulating the immune system.

A global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics.

Leveraging the adaptive immune system to diagnose and treat disease.

A global oncology company developing and commercializing innovative cancer treatments.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global biotechnology company pioneering innovative medicines for complex neurological, neuropsychiatric, and rare diseases.

Global biopharmaceutical company focused on oncology, rare diseases, and neuroscience.

Develops long-acting implantable and injectable therapies for opioid addiction and chronic pain.

Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry medicines for mental health conditions.

A biotechnology company developing small molecule drugs to treat neurodegenerative diseases by targeting mitochondrial dysfunction.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Clinical-stage biopharma developing precisely designed cancer therapeutics using a proprietary cell-free protein synthesis platform.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

H1 is a healthcare data platform that connects life sciences companies with healthcare professionals.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Global immunology company developing antibody-based therapies for severe autoimmune diseases.

Cradle Bio B.V. is a Dutch, Swiss biotechnology company that develops software using machine learning for protein engineering. It was founded in 2021 and is base

Developing first-in-class oral therapy for BK polyomavirus infections.

Immunotherapy company targeting oncology and autoimmune diseases.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.

Developing novel male contraceptives.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Develops an endovascular solution for vasospasm treatment in aneurysmal subarachnoid hemorrhage.

A biopharmaceutical company focused on drug discovery and development.

Advancing targeted alpha therapies.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

AI-guided drug discovery platform for tissue-targeted medicines.

Developing engineered biologics to harness the immune system for disease treatment.

Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.

Clinical-stage biotech company developing transformative cytokine therapies.